References
- Stelara: US Prescribing Information. Aug 2022. https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/STELARA-pi.pdf Accessed 27 Mar 2023.
- Stelara: summary of Product Characteristics. Apr 2020. (https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf) Accessed 27 Mar 2023.
- FDA. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product – Guidance for Industry. Apr 2015. (https://www.fda.gov/media/82647/download) Accessed 27 Mar 2023.
- EMA. Guideline on similar biological medicinal products. Apr 2015. (https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-rev1_en.pdf) Accessed 27 Mar 2023.
- WHO. Guidelines on evaluation of similar biotherapeutic products (SBPs). Jan 2010. (https://cdn.who.int/media/docs/default-source/biologicals/trs_977_annex_2.pdf?sfvrsn=e2389a69_3&download=true). Accessed 27 Mar 2023.
- PMDA. Basic Principles on Global Clinical Trials. Sep 2007. (https://www.pmda.go.jp/files/000157900.pdf) Accessed 27 Mar 2023.
- FDA. Bioanalytical Method Validation – Guidance for Industry. May 2018. (https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf) Accessed 28 Mar 2023.
- EMA. Guideline on bioanalytical method validation. Jul 2011. (https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf) Accessed 28 Mar 2023.
- Marini JC, Anderson M, Cai XY, et al. Systematic verification of bioanalytical similarity between a biosimilar and a reference biotherapeutic: committee recommendations for the development and validation of a single ligand-binding assay to support pharmacokinetic assessments. Aaps J. 2014 Nov;16(6):1149–1158.
- Civoli F, Kasinath A, Cai XY, et al. Recommendations for the development and validation of immunogenicity assays in support of biosimilar programs. Aaps J. 2019 Dec 2;22(1):7. DOI:10.1208/s12248-019-0386-y
- EMA. Guideline on similar biological medicinal products containing monoclonal antibodies – non-clinical and clinical issues. May 2012. (https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinal-products-containing-monoclonal-antibodies-non-clinical_en.pdf) Accessed 28 Mar 2023.
- Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Review(s). Nov 2018. (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/204417Orig1s000ClinPharmR.pdf) Accessed 28 Mar 2023.
- Zhu Y, Wang Q, Frederick B, et al. Comparison of the pharmacokinetics of subcutaneous ustekinumab between Chinese and non-Chinese healthy male subjects across two Phase 1 studies. Clin Drug Investig. 2013 Apr;33(4):291–301.
- Shankar G, Arkin S, Cocea L, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. Aaps J. 2014 Jul;16(4):658–673.
- Lyman GH, Balaban E, Diaz M, et al. American Society of Clinical Oncology Statement: biosimilars in Oncology. J Clin Oncol. 2018 Apr 20;36(12):1260–1265.
- Campen CJ. Integrating Biosimilars into Oncology Practice: implications for the Advanced Practitioner. J Adv Pract Oncol. 2017 Nov;8(7):688–699.
- Berti F, Wynne C, Stroissnig H, et al.; Assessment of bioequivalence between candidate biosimilar AVT04 and reference ustekinumab. Presented at: AAD 2023; Mar 17-21, 2023. https://eposters.aad.org/abstracts/42601. Accessed 25 Apr 2023.
- Stroissnig H, Feldman S, Berti F, et al.; Assessment of therapeutic equivalence between candidate biosimilar AVT04 and reference ustekinumab. Presented at: AAD Mar 17-21, 2023. https://eposters.aad.org/abstracts/42913. Accessed 25 Apr 2023.